Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking

Lee P Richman1, Robert H Vonderheide1

  • 1Abramson Family Cancer Research Institute; Perelman School of Medicine; University of Pennsylvania; Philadelphia, PA USA.

Oncoimmunology
|August 7, 2014
PubMed